Navigation Links
Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
Date:11/28/2008

AMSTERDAM, Nov. 28 /PRNewswire/ -- Oncology focused biopharmaceutical company Kiadis Pharma announces today that Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia, Italy and Kiadis Pharma are continuing their collaboration on ATIR(TM), a product in clinical development for enabling the use of a mismatched donor in a bone marrow transplantation by preventing acute Graft versus Host Disease (GvHD) for end stage leukemia patients. Under the agreement Professor Velardi will continue the development on the selective depletion of allo-reactive T cells from mismatched donors using Kiadis Pharma's ATIR(TM). Kiadis Pharma is preparing for a multi-center pivotal study on ATIR(TM) to start early 2009 and Professor Velardi will participate in this upcoming study.

"We are very pleased with our continued collaboration with the University of Perugia and Professor Velardi, who is a leader in the field of mismatched bone marrow transplantations," says Dr. Manja Bouman, CEO of Kiadis Pharma. "This collaboration is an important milestone in the development of ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients."

Professor Andrea Velardi says: "So far, we have treated 25 blood cancer patients who have received bone marrow from mismatched donors, including donor immune cells that are selectively depleted of cells causing acute Graft versus Host Disease using the ATIR(TM) process. The results so far are promising and I am therefore very pleased to continue to work with Kiadis Pharma in this field."

For the complete press release please go to: www.kiadis.com/news

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different p
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Array BioPharma Inc. (NASDAQ: ARRY ... agreement with Novartis Pharma AG to acquire worldwide rights ... 3 development.  This agreement is conditional on the closing of ... 22, 2014, which are expected to close in the ...
(Date:1/22/2015)... Shimadzu Scientific Instruments today announces the ... Offering wavelength scanning from 190 to 1,100 nm, ... in a variety of industries, including environmental, food ... enables intuitive operation, while the enhanced validation, maintenance ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces the ... office space for Shire a leading biopharmaceutical company, at Two ... | RBJ,s Robert Richards , president, and Brian ... for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2
... PharmAthene, Inc. (NYSE Amex: PIP ), ... threats, today reported financial and operating results for the first ... first quarter of 2011 PharmAthene recognized revenue of $6.3 million ...  Revenues for the most recent quarter consisted of contract funding ...
... HCCS (Health Care Compliance Strategies, Inc.), the ... training and tracking solutions, today announced the release ... a web-based system for the management and real-time ... this comprehensive tool in response to tighter government ...
... ROCKVILLE, Md., May 11, 2011 Novavax, Inc. (Nasdaq: ... of the Year by the Tech Council of Maryland ... technology and biotechnology communities of Maryland.  Novavax was recognized ... the Maryland biotechnology community and for its presence and ...
Cached Biology Technology:PharmAthene Reports First Quarter 2011 Financial and Operating Results 2PharmAthene Reports First Quarter 2011 Financial and Operating Results 3PharmAthene Reports First Quarter 2011 Financial and Operating Results 4PharmAthene Reports First Quarter 2011 Financial and Operating Results 5PharmAthene Reports First Quarter 2011 Financial and Operating Results 6Conflict of Interest Disclosures Tool Updated 2Novavax Named Biotechnology Firm of the Year by Tech Council of Maryland 2
(Date:12/17/2014)... SM announced today its completion of a Good ... current U.S. Food and Drug Administration (FDA) regulations. This ... smart phone application trials utilizing the highest principles for ... determined to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming the ... at international borders. Over the past decade, ePassports, biometric ... to self process through border control via eGates and ... of airports, seaports, and land borders across the globe. ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. One major ... multimodal biometric systems. Multimodal biometric systems utilize more than ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... retirees, and other volunteers who are taking part in ... certain plants are blooming unusually early, perhaps as a ... the timing of flowers and foliage, amassing thousands of ... detailed picture of our changing climate. The project, ...
... release is available in Spanish . , ... generated artificial human skin by tissular engineering basing on agarose-fibrin ... development, maturation and functionality results were obtained. This pioneering finding ... use in many laboratory tests on biological tissues which, additionally, ...
... PROVIDENCE, R.I. [Brown University] Brown University professors Donald ... the American Academy of Arts and Sciences, the Cambridge, ... thinkers in scholarship and science, public affairs and business, ... James L. Manning professor of geological sciences, specializing in ...
Cached Biology News:'10 most wanted' plants inspected for clues to climate change 2'10 most wanted' plants inspected for clues to climate change 3Scientists create artificial human skin with biomechanical properties using tissue engineering 2Brown scientists elected to American Academy of Arts and Sciences 2
Ultra-sensitive, non-radioactive detection of rat Big Endothelin-1 (Big ET-1)...
Request Info...
Request Info...
Peptide Sequence: ovine COX-1 amino acids 272-282 (LMHYPRGIPPQ) To be used in conjunction with Cayman's COX-1 (ovine) polyclonal antiserum (Catalog No. 160108) to block protein-antibody complex f...
Biology Products: